





2nd SA NANO HIV/AIDS 2016

SYMPOSIUM ON NANOMEDICINE AND HIV/AIDS IN SOUTH AFRICA

Venue: SAASTA, Didacta Building, 211 Nana Sita Street, Pretoria

02 DECEMBER 2016; Time: 08:30-17:30



08:00-08:50			Arrival and Registration		
Programme Facilitator: Dr Mthuthuzeli Zamxaka					
Time	Activity	Presenter			
08:50-09:00	Welcome remarks	<i>Dr Mthuthuzeli Zamxaka: NPEP</i>			
09:00-09:20	Role of SAASTA in the National System of Innovation	<i>Dr Jabu Nukeri: MD SAASTA</i>			
09:20-09:40	UNAIDS strategy toward making HIV history	<i>Dr Erasmus Mora: UNAIDS</i>			
09:40-10:00	Current status of HIV/AIDS in South Africa	<i>Dr Rufaro Chatora: WHO</i>			
10:00-10:20	South African National AIDS Council	<i>Dr Fareed Addullah: SANAC</i>			
10:20-10:40	Discussion	<i>All</i>			
10:40 -11:00 Tea Break					
Programme Facilitator: Prof Thomas Franz: UCT					
11:00-11:20	Current work on viral mechanics - HIV	<i>Lee Kruse: UCT</i>			
11:20-11:40	Bill & Melinda Gate Foundation: Grant funding opportunities in HIV/AIDS research	<i>Moky Makura: Gate Foundation</i>			
11:40-12:00	Nanotechnology: Research and postgraduate funding	<i>Ms Rebacca Molubi: NRF</i>			
12:00-12:20	Pro-apoptotic nano-devices to HIV infected cells	<i>Prof Mervin Meyer: UWC</i>			
12:20-12:40	Aptamer-based nanobiosensor for the detection of HIV	<i>Prof Omotayo Arotiba: UJ</i>			
12:40-13:00	Nanomedicine for TB treatment , A major Co-Infection for HIV	<i>Dr Phuti Chelopo: CSIR</i>			
13:00-13:20	Discussion	<i>All</i>			
13:20-14:20 Lunch Break					
Programme Facilitator: Prof Mervin Meyer: UWC					
14:20-14:40	Amnis® imaging flow cytometers and nanomaterials	<i>Dr John Walters: Merck</i>			
14:40-15:00	Preclinical and clinical development for nanopharmaceutical	<i>Prof Rose Hayeshi: NWU</i>			
15:00-15:20	HIV/AIDS and nanobacteria	<i>Prof Anne-Marie Pretorius: UFS</i>			
15:10-15:30	Risk assessment of nanomaterials	<i>Prof Ndeke Musee: UP</i>			
15:30-15:45 Tea Break					
Programme Facilitator: Dr Steven Mufamadi: Nabio Consulting					
15:45-16:50	The DTI: Commercialising Innovative Research	<i>Dr Tshenge Demana: The DTI</i>			
16:00-16:20	Truvada and HIV/AIDS eradication: Gilead Sciences (GS) perspective	<i>Mr Danielle Lubbe: Gilead Sciences</i>			
16:20-16:40	HIV/AIDS and antiretroviral treatment: Glaxo Smith Kline (GSK) perspective	<i>Dr Santoshni Govindasam: GSK</i>			
16:40-17:00	Science communication for researchers and industry	<i>Mr Robert Englis: Jive Media</i>			
17:00-17:20	Discussions	<i>All</i>			
17:20-17:30	Closure and vote of thanks	<i>Mr. Michael Elis: SAASTA</i>			